Kisspeptin Reconstitution Calculator
Kisspeptin has published human doses, and almost none of them match how the compound is actually bought and used. It is the endogenous ligand for KISS1R on hypothalamic GnRH neurons, one level upstream of the pituitary, and giving it to a person raises LH within minutes. The catch is in the detail. Kisspeptin-10, the form sold as a research chemical, has been given to humans intravenously only: this library holds no subcutaneous kisspeptin-10 study at all. The subcutaneous human data is all kisspeptin-54, a different and larger peptide, dosed throughout in nanomoles per kilogram, and the published corpus never states the molecular weight needed to convert that into a mass. The one range below is therefore an intravenous research dose, weight-scaled and shown for a 70 kg adult. No kisspeptin product is approved anywhere. The calculator on this page converts a vial size and a mixing volume into mg/ml and U-100 syringe units, which is arithmetic about a vial and not a dose.
Curated by Dosavy from published literature and regulator labels. Published 11 September 2026, last reviewed 11 September 2026. No clinician reviews this page.
Enter a target dose above to see the draw.
What the evidence says
| Experience | Route | Range | Frequency |
|---|---|---|---|
| Beginner | Intravenous | 21–70 mcg[1][2][3]Source doses, verbatim: 0.3 micrograms/kg (men with type 2 diabetes and matched healthy men) and 1 microgram/kg (healthy men across three age bands; the dose of maximal LH response in a 0.01-3.0 micrograms/kg dose-finding study). The figures shown, 21-70 mcg, are those doses for a 70 kg adult and MUST be recalculated for actual body weight. Route: intravenous. This is not a subcutaneous dose and no subcutaneous kisspeptin-10 study exists. Two further findings bound this range. Going higher backfires: 3 micrograms/kg produced a SMALLER LH response than 1 microgram/kg. And continuous infusion is a different regimen entirely: 1.5 micrograms/kg/hour raised LH pulse frequency, while 4 micrograms/kg/hour over 22.5 hours raised LH roughly fourfold and testosterone by about 45%, but obscured pulsatility. | Single intravenous bolus |
- BeginnerIntravenous
Single intravenous bolus
Source doses, verbatim: 0.3 micrograms/kg (men with type 2 diabetes and matched healthy men) and 1 microgram/kg (healthy men across three age bands; the dose of maximal LH response in a 0.01-3.0 micrograms/kg dose-finding study). The figures shown, 21-70 mcg, are those doses for a 70 kg adult and MUST be recalculated for actual body weight. Route: intravenous. This is not a subcutaneous dose and no subcutaneous kisspeptin-10 study exists. Two further findings bound this range. Going higher backfires: 3 micrograms/kg produced a SMALLER LH response than 1 microgram/kg. And continuous infusion is a different regimen entirely: 1.5 micrograms/kg/hour raised LH pulse frequency, while 4 micrograms/kg/hour over 22.5 hours raised LH roughly fourfold and testosterone by about 45%, but obscured pulsatility.
Published ranges, reported as the literature states them and numbered to the sources at the foot of this page. Not a recommendation.
Kisspeptin has a substantial randomised human literature (roughly twenty trials in this corpus), but almost none of it maps onto how the compound is actually bought and used. Kisspeptin-10, the form sold as a research chemical, has been given to humans only intravenously (bolus 0.01-3.0 micrograms/kg, or infusion at 1.5-4 micrograms/kg/hour); the corpus contains no subcutaneous kisspeptin-10 study at all. Kisspeptin-54, which HAS been given subcutaneously (bolus and 8-hour infusion, and twice-daily or twice-weekly for up to 8 weeks), is dosed throughout in nanomoles per kilogram (0.15 to 12.8 nmol/kg), and this corpus never states the molecular weight required to convert that to a mass dose, so no subcutaneous range is published here rather than publish a number derived from a molecular weight recalled from outside the evidence. The intravenous kisspeptin-10 range below is the only one this packet supports, and it is a research administration route.
Kisspeptin at a glance
- Category
- Hormone
- Half-life
- 0.5 h
- Routes
- Other, Subcutaneous, Intranasal
- Regulatory status
- Research use only
- Also sold as
- Kisspeptin-10, KP-10, Kisspeptin-54, KP-54, Metastin
Mechanism
Kisspeptin is the endogenous ligand for KISS1R (GPR54) on hypothalamic GnRH neurons and sits one level upstream of everything gonadorelin does: it stimulates GnRH release, which drives pituitary LH and FSH, which drive gonadal steroidogenesis. Loss-of-function mutations in the receptor cause failure of reproductive function, which is how the pathway was identified. Human administration reliably and rapidly raises LH: in men a bolus roughly triples serum LH within 30 minutes and continuous infusion raises LH pulse frequency, pulse size and testosterone. Repeated exposure, however, desensitises the pathway: twice-daily administration abolished the FSH response within about two days and blunted the LH response over two weeks.
Reconstitution
Supplied as a lyophilised research powder with no approved label. Note that 'kisspeptin' names at least two different molecules, kisspeptin-10 (KP-10) and kisspeptin-54 (KP-54), which are not equimolar, are not dosed alike in the literature, and are frequently sold interchangeably. Confirm which one a vial contains before doing any dose arithmetic.
Storage
No approved product exists, so there is no manufacturer storage direction. Research-grade material is supplied lyophilised and is typically stored frozen before reconstitution and refrigerated afterwards, on the supplier's word alone.
Frequency in practice
In trials, a single bolus or a continuous infusion of a few hours to a day. Repeated dosing more often than about twice weekly causes tachyphylaxis, so there is no established daily regimen.
Regulatory
No kisspeptin product is approved by the FDA, EMA or Swissmedic for any indication. All human use to date has been in investigator-led clinical research or industry phase 1/2 programmes, mostly in reproductive medicine (as an ovulation trigger that does not cause ovarian hyperstimulation syndrome) and, more recently, in hypoactive sexual desire disorder. Material sold to consumers is research chemical supply outside any regulatory framework.
What to know before anything else
Not approved for human use anywhere. Every dose in this entry comes from a supervised clinical trial with intravenous or research-grade subcutaneous administration and monitoring, not from a product intended for self-administration.
Tachyphylaxis is the central pharmacological problem, not a footnote. With twice-daily subcutaneous kisspeptin-54, the FSH response was nearly abolished by day 2 and the LH response fell roughly tenfold by day 14. Dosing it like a daily peptide predictably stops it working.
The consumer research-chemical form is kisspeptin-10, and there is no published human trial of kisspeptin-10 given subcutaneously. The subcutaneous human data is all kisspeptin-54, a different and larger peptide.
Kisspeptin drives the entire reproductive axis. It has been used to trigger ovulation in IVF cycles, and it raises LH, FSH and testosterone in men. It should not be treated as an inert 'libido peptide'.
Effects on mood and anxiety have been actively looked for and not found: in 95 participants a biologically active infusion did not change state anxiety, cortisol, blood pressure or heart rate. Claims of anxiolytic benefit are not supported.
Long-term safety is unstudied. The longest published human exposure in this corpus is eight weeks of twice-weekly dosing in a small group of women with hypothalamic amenorrhoea.
Kisspeptin questions
Is there an established human dose for kisspeptin?
There is a published one, and it is narrower than it looks. The range above is an intravenous bolus of kisspeptin-10 given in supervised clinical research, and it is weight-scaled: the source figures are micrograms per kilogram, shown here for a 70 kg adult and requiring recalculation for actual body weight. It is not a subcutaneous dose, and no subcutaneous kisspeptin-10 study exists to supply one.
How does kisspeptin work?
Kisspeptin binds KISS1R, also called GPR54, on hypothalamic GnRH neurons. That stimulates GnRH release, which drives pituitary LH and FSH, which in turn drive gonadal steroidogenesis. Loss-of-function mutations in the receptor cause failure of reproductive function, which is how the pathway was identified in the first place. In men a bolus roughly triples serum LH within 30 minutes, and continuous infusion raises LH pulse frequency, pulse size and testosterone. It moves the entire reproductive axis rather than one symptom, which is why it should not be treated as an inert libido peptide.
What human trials of kisspeptin exist?
Roughly twenty randomised trials sit in this library's corpus, and three of them carry the range above. A 2011 dose-finding clinical trial in The Journal of Clinical Endocrinology and Metabolism gave intravenous kisspeptin-10 boluses to six healthy men and found a dose-dependent LH rise with a clear maximum, above which the response became smaller rather than larger. A 2013 Clinical Endocrinology trial in twelve men compared healthy men with men who had type 2 diabetes and mild biochemical hypogonadism. A 2019 Andrologia study gave a single bolus across three age bands and raised LH in all of them, but raised testosterone only in the youngest group, since Leydig cell responsiveness to kisspeptin-driven LH declines with age. Those trials also ran continuous infusions rather than boluses, which is a different regimen with different results: one infusion rate raised LH pulse frequency, while a faster rate over 22.5 hours raised LH roughly fourfold and testosterone by about 45% but obscured pulsatility.
Is kisspeptin-10 the same as kisspeptin-54?
No, and confusing the two is the most consequential mistake available on this compound. They are different molecules, they are not equimolar, they are not dosed alike in the literature, and they are frequently sold interchangeably under the single word kisspeptin. The intravenous evidence is kisspeptin-10; the subcutaneous evidence is kisspeptin-54. Confirm which one a vial contains before doing any arithmetic with it.
Why does kisspeptin stop working after a few days?
Tachyphylaxis, and it is the central pharmacological problem here rather than a footnote. With twice-daily subcutaneous kisspeptin-54, the FSH response was nearly abolished by day 2 and the LH response fell roughly tenfold by day 14. Dosing it like a daily peptide predictably stops it working. In trials the regimens were a single bolus, an infusion of a few hours to a day, or repeat dosing no more often than about twice weekly.
Does kisspeptin help libido, mood or anxiety?
Desire is under investigation; anxiety has been looked for and not found. The recent human work has run in hypoactive sexual desire disorder, alongside older reproductive-medicine studies using kisspeptin as an ovulation trigger that does not cause ovarian hyperstimulation syndrome. Both are investigational, and no product is approved for either. The mood claim is the one with a direct answer: in 95 participants, a biologically active infusion produced no change in state anxiety, cortisol, blood pressure or heart rate, so claims of anxiolytic benefit are not supported by the evidence that exists.
What is known about long-term kisspeptin safety?
Very little, and the honest answer is that the question has not been studied. The longest published human exposure in this library's corpus is eight weeks of twice-weekly dosing in a small group of women with hypothalamic amenorrhoea. Every dose in the record comes from a supervised clinical trial using intravenous or research-grade subcutaneous administration with monitoring, not from a product intended for self-administration. No kisspeptin product is approved by the FDA, EMA or Swissmedic for any indication, and what is sold to consumers is research chemical supply outside any regulatory framework.
Every number above, and where it came from
3 sources, numbered where they are used. Each one links to the paper or the label itself, not to a summary of it.
- [1]Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
The Journal of Clinical Endocrinology and Metabolism · 2011 · Clinical trial, dose-finding · n=6
- [2]Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism
Clinical Endocrinology · 2013 · Clinical trial · n=12
- [3]Age-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men
Andrologia · 2019 · Clinical trial
The rest of the math
- Reconstitution calculatorThe full version of the tool above, with syringe barrel sizes and IU conversion.
- Vial longevityHow many doses a vial holds and the date it runs out.
- Cost per doseVial price against doses drawn, so two vial sizes can be compared honestly.
- Half-life and decayFirst-order clearance, time to steady state, and what remains at a given hour.
Same class as Kisspeptin
You worked out the draw. Now log this dose.
A calculator answers once and forgets. Dosavy keeps the concentration you mixed, the doses you actually took, and a reminder for the next one, with the same evidence labels you see on this page.